SGBI News Alert Sangui Biotech Intl Inc (SGBI) 0.0573 02/15/2015
Post# of 64074
Posted On: 02/15/2015 1:21:42 PM
Sangui Biotech Intl Inc (SGBI) 0.0573 $SGBI
Sangui BioTech: Revenues Slightly Improved in the First Half of the 2015 Financial Year
Business Wire - Thu Feb 12, 5:00AM CST
For the first half (as of December 31, 2014) of its 2015 financial year Sangui BioTech International, Inc. reports revenues from product sales and royalties in the amount of USD104,906 an increase of 74.0% over the revenues in the first half of the financial year 2014. In the second quarter (October through December 2014) revenues amounted to USD31,166 a decrease of 57.7% as compared with the most recent quarter(July through September 2014).
Sangui BioTech: Revenues Improved in the First Quarter of the 2015 Financial Year
Business Wire - Thu Nov 13, 5:00AM CST
For the first quarter (as of September 30, 2014) of its 2015 financial year Sangui BioTech International, Inc. reports revenues from product sales and royalties in the amount of USD73,470 (Q1/2013: USD26,527). This is an improvement of 73% as compared with the fourth quarter of the previous financial year (as of June 30, 2014).
SBH: 33.10 (+0.28)
Sangui BioTech International officially approved as trading on OTCQB
Business Wire - Thu Nov 06, 5:36AM CST
OTC Markets Group has officially informed Sangui Biotech International, Inc., that the application of the company for continued trading on the OTCQB venture market place for early stage and developing companies was approved of today. Subsequent to the reorganization of the OTC markets, resulting in higher transparency levels and significantly improved services for issuers and investors in particular on OTCQB, Sangui has submitted all the mandatory documents and successfully met all of the initial requirements.
SBH: 33.10 (+0.28)
Sangui BioTech Yields Revenues of over USD70,000 in Q1 2015 According to Preliminary Figures
Business Wire - Tue Oct 07, 1:22PM CDT
According to preliminary, unaudited figures Sangui BioTech International, Inc. yielded revenues from royalties and product sales of more than USD70,000 in the course of the first quarter of its financial year 2015, ended September 30, 2014. In the fourth quarter of the 2014 financial year (ended June 30, 2014) revenues had amounted to USD43,729; in the first quarter of its financial year 2014 (ended September 30, 2014) the company reported revenues of USD26,527.
SanguiBioTech yields revenues of around USD42,000 in Q4 2014 according to preliminary figures
Business Wire - Tue Jul 29, 10:50AM CDT
According to preliminary, unaudited figures Sangui Biotech International, Inc. yielded revenues from royalties and product sales of USD42,000 in the course of the fourth quarter of its financial year 2014, ended June 30, 2014. In the third quarter (ended March 31, 2014) revenues had amounted to USD29,438; in the fourth quarter of its financial year 2013 (ended June 30, 2013) the company reported revenues of USD24,056. Based on this preliminary state of accounting Sangui will presumably present revenues of more than USD130,000 for its 2014 financial year (FY 2013: USD105,487).
Sangui BioTech: Revenues Slightly Improved in the First Half of the 2015 Financial Year
Business Wire - Thu Feb 12, 5:00AM CST
For the first half (as of December 31, 2014) of its 2015 financial year Sangui BioTech International, Inc. reports revenues from product sales and royalties in the amount of USD104,906 an increase of 74.0% over the revenues in the first half of the financial year 2014. In the second quarter (October through December 2014) revenues amounted to USD31,166 a decrease of 57.7% as compared with the most recent quarter(July through September 2014).
Sangui BioTech: Revenues Improved in the First Quarter of the 2015 Financial Year
Business Wire - Thu Nov 13, 5:00AM CST
For the first quarter (as of September 30, 2014) of its 2015 financial year Sangui BioTech International, Inc. reports revenues from product sales and royalties in the amount of USD73,470 (Q1/2013: USD26,527). This is an improvement of 73% as compared with the fourth quarter of the previous financial year (as of June 30, 2014).
SBH: 33.10 (+0.28)
Sangui BioTech International officially approved as trading on OTCQB
Business Wire - Thu Nov 06, 5:36AM CST
OTC Markets Group has officially informed Sangui Biotech International, Inc., that the application of the company for continued trading on the OTCQB venture market place for early stage and developing companies was approved of today. Subsequent to the reorganization of the OTC markets, resulting in higher transparency levels and significantly improved services for issuers and investors in particular on OTCQB, Sangui has submitted all the mandatory documents and successfully met all of the initial requirements.
SBH: 33.10 (+0.28)
Sangui BioTech Yields Revenues of over USD70,000 in Q1 2015 According to Preliminary Figures
Business Wire - Tue Oct 07, 1:22PM CDT
According to preliminary, unaudited figures Sangui BioTech International, Inc. yielded revenues from royalties and product sales of more than USD70,000 in the course of the first quarter of its financial year 2015, ended September 30, 2014. In the fourth quarter of the 2014 financial year (ended June 30, 2014) revenues had amounted to USD43,729; in the first quarter of its financial year 2014 (ended September 30, 2014) the company reported revenues of USD26,527.
SanguiBioTech yields revenues of around USD42,000 in Q4 2014 according to preliminary figures
Business Wire - Tue Jul 29, 10:50AM CDT
According to preliminary, unaudited figures Sangui Biotech International, Inc. yielded revenues from royalties and product sales of USD42,000 in the course of the fourth quarter of its financial year 2014, ended June 30, 2014. In the third quarter (ended March 31, 2014) revenues had amounted to USD29,438; in the fourth quarter of its financial year 2013 (ended June 30, 2013) the company reported revenues of USD24,056. Based on this preliminary state of accounting Sangui will presumably present revenues of more than USD130,000 for its 2014 financial year (FY 2013: USD105,487).
(0)
(0)Scroll down for more posts ▼